Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Renal-Cell Carcinoma
Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment
Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP
Read More
Meeting Highlights
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Read More
Meeting Highlights
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Read More
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Read More
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Read More
Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma
Read More
1
2
3
Page 3 of 3
Results 21 - 26 of 26